iRhythm Holdings, Inc. (IRTC)

In the past six months, iRhythm announced its Q4 and full year 2025 financial results, reporting a revenue increase and positive GAAP net income. The company had a presence at the ACC.26 conference, presenting new Zio clinical data and announcing AI partnerships. Jason Patten was appointed to iRhythm's Board of Directors. The stock experienced a share price decline. The company has faced a DOJ subpoena overhang and ongoing regulatory remediation, and insiders have sold more stock than purchased.

iRhythm Holdings, Inc. experiences some demand seasonality, with third-quarter revenue typically slightly lower than the second quarter. Overall demand for Zio services has been strong, contributing to significant revenue increases. The company has observed increased volume growth across its U.S. core business, innovative health channels, and international markets.

iRhythm Holdings, Inc. is a digital healthcare company specializing in device-based technology for ambulatory cardiac monitoring services. The company's core business revolves around the Zio System, an FDA-cleared and CE-marked biosensor that records ECG data for up to 14 days. The Zio XT System is a prescription-only remote ECG monitoring system. The Zio AT System incorporates a wireless gateway for real-time data transmission. The company is also developing the Zio Watch.

iRhythm Holdings, Inc. is headquartered in San Francisco, California, with additional U.S. offices in Chicago, Cypress, Houston, and Solana Beach. Internationally, iRhythm has a commercial presence in the United Kingdom, selected European countries, and Japan. The company also has an office in Mandaluyong, Philippines.

iRhythm Holdings, Inc. has maintained a strong brand reputation as a leading digital health care company. The company highlights its unique iRhythm monitoring service, which utilizes an advanced FDA-cleared AI. The ongoing DOJ subpoena overhang and regulatory remediation could be perceived as potential reputational risks.

iRhythm Holdings, Inc. has a significant institutional ownership base, including Vanguard Group Inc and BlackRock, Inc. Key individual or insider owners include Synergy Life Science Partners L P and Holdings A. Novo.